Fulgent Genetics Inc (FLGT) reports a 14% annual revenue increase, strategic acquisitions, and new market opportunities ...

HYDERABAD: Researchers at AIG Hospitals have found that inherited genetic susceptibility interacts with lifestyle factors to ...

Management's prepared remarks and answers to your questions on today's call will contain forward-looking statements. As a ...

Q4 2025 earnings call highlights: 2026 revenue outlook, Bako/StrataDx deals, AI pathology gains, and customer-loss risks—read now.

As of Friday, February 27, Fulgent Genetics, Inc.’s FLGT share price has dipped by 31.34%, which has investors questioning if this is right time to buy.

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or ...

Shares of Fulgent Genetics tumbled after the company recorded a wider net loss in the fourth quarter and guided for lower-than-expected results in 2026. The stock plunged 32% to $16.84 in Friday ...

Myriad Genetics delivered a solid Q4 2025 earnings beat, with positive adjusted EPS and strong test volume growth. Click for ...

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and str ...

Geneticists have a better understanding of how prehistoric pairings unfolded, with new research suggesting they were mostly ...

The study offers one of the most detailed maps yet of how human antibody responses vary from person to person.